Chau, I., Peck-Radosavljevic, M., Borg, C., Malfertheiner, P., Seitz, J. F., Park, J. O., Ryoo, B., Yen, C., Kudo, M., Poon, R., Pastorelli, D., Blanc, J., Chung, H. C., Baron, A. D., Okusaka, T., Bowman, L., Cui, Z. L., Girvan, A. C., Abada, P. B., Yang, L., & Zhu, A. X. (2018). corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17–25]. European journal of cancer, 100, 135–136. http://access.bl.uk/ark:/81055/vdc_100066537999.0x000022